Creatv Announces Five Clinical Data Presentations at ASCO 2026

Creatv Bio, a Division of Creatv MicroTech, Inc. ("Creatv"), a cancer diagnostic blood testing company, is pleased to announce one poster presentation and four poster abstracts in conjunction with it's pharmaceutical company collaborators at the upcoming 2026 ASCO Annual Meeting, May 29-June 2, 2026, McCormick Place, Chicago, Illinois.

Abstract Title: Monitoring blood-based biomarkers as early predictors of progression-free survival in a randomized Bria-ABC phase 3 trial for advanced metastatic breast cancer: An ongoing analysis
Abstract: 2652
Session Title: Developmental Therapeutics—Immunotherapy
Poster Board: 442
Date and Time: May 30, 2026, 1:30 PM – 4:30 PM CDT

Poster Abstracts in Collaboration with BriaCell, a clinical-stage immuno-oncology drug company:

Abstract Title: Monitoring PD-L1 expression in circulating cancer associated cells for prediction of clinical outcomes in metastatic breast cancer patients treated with immune checkpoint inhibitors
Abstract: e14535

Abstract Title: Liquid biopsy to stratify metastatic breast cancer progression risk using multi-analyte cell subtyping prior to systemic therapy
Abstract: e15525

Poster Abstracts in Collaboration with CytoDyn, a biotechnology company developing innovative treatments for cancer.

Abstract Title: Safety and 5-year survival following treatment with leronlimab plus physician's choice combination therapy in patients with metastatic triple-negative breast cancer
Abstract: e14535

Abstract Title: Leronlimab in combination with trifluridine/tipiracil (TAS-102) plus bevacizumab for patients with refractory metastatic colorectal cancer (mCRC): The phase 2 CLOVER study
Abstract: e13109

Creatv Bio's LifeTracDx® blood test, described in the abstracts above, was used in the various studies to rapidly develop companion/complementary diagnostic tools for specific cancer therapies and provided continuous monitoring of cancer patients for pharmaceutical companies to optimize therapy regimes.